Muhammad Nadeem Shamsi, MD
Psychiatry · Plymouth Meeting, PANPI 1609843721
Payments from drug & device makers
Across 486 payments — averaging $34.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$6K
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Neuronetics, Inc.$857
- Otsuka America Pharmaceutical, Inc.$719
- Teva Pharmaceuticals USA, Inc.$594
- plus $6K from 22 others
What the payments were for
- Speaking & faculty fees$4,27525%
- Travel & lodging$1,3208%
- Food & beverage$11,12266%
- Education$590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 23 | $6,058 |
| AbbVie(2 entities) | 111 | $1,471 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 52 | $1,459 |
| Neuronetics, Inc. | 14 | $857 |
| Otsuka America Pharmaceutical, Inc. | 29 | $719 |
| Teva Pharmaceuticals USA, Inc. | 23 | $594 |
| Alkermes, Inc. | 21 | $499 |
| Johnson & Johnson | 22 | $493 |
| Lundbeck LLC | 25 | $469 |
| E.r. Squibb & Sons, L.L.C. | 9 | $467 |
| Neurocrine Biosciences, Inc. | 15 | $450 |
| Corium, LLC | 18 | $414 |
| Sunovion Pharmaceuticals Inc. | 24 | $389 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $338 |
| Axsome Therapeutics, Inc. | 8 | $282 |
| Vanda Pharmaceuticals Inc. | 8 | $254 |
| Merck | 14 | $253 |
| Boston Scientific | 4 | $234 |
| Tris Pharma Inc | 11 | $207 |
| Almatica Pharma LLC | 8 | $182 |
| Neos Therapeutics, LP | 8 | $175 |
| Adlon Therapeutics L.p. | 7 | $139 |
| Eisai Inc. | 6 | $127 |
| Idorsia Pharmaceuticals US Inc | 4 | $77 |
| Ironshore Pharmaceuticals Inc. | 3 | $71 |
| Jazz Pharmaceuticals Inc. | 2 | $62 |
| Noven Therapeutics, LLC | 1 | $23 |
| Vertical Pharmaceuticals, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,776 in reported general payments places this provider in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 18 | $148,372 |
| Invega SustennaPaliperidone Palmitate | 45 | $128,286 |
| AustedoDeutetrabenazine | 13 | $93,911 |
| VraylarCariprazine Hcl | 36 | $50,813 |
| CaplytaLumateperone Tosylate | 13 | $19,019 |
| Aripiprazole | 239 | $15,890 |
| TrintellixVortioxetine Hydrobromide | 31 | $14,845 |
| Quetiapine Fumarate | 668 | $11,117 |
| QuviviqDaridorexant Hcl | 14 | $6,239 |
| Olanzapine | 444 | $6,181 |
| Divalproex Sodium ErDivalproex Sodium | 64 | $5,767 |
| Divalproex Sodium | 119 | $5,711 |
| Lurasidone Hcl | 53 | $5,703 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,527 |
| Fluvoxamine Maleate ErFluvoxamine Maleate | 52 | $4,482 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $594 | $242,28331 claims |
| Johnson & JohnsonInvega Sustenna, Invega | $493 | $132,62657 claims |
| AbbVieVraylar | $1,471 | $50,81336 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $338 | $19,37243 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,459 | $19,01913 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $77 | $6,23914 claims |
| Eisai Inc.Dayvigo | $127 | $3,98612 claims |
| Almatica Pharma LLCSertraline Hcl | $182 | $1,580159 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Other psychiatry in Plymouth Meeting
- Joseph VolpicelliPlymouth Meeting$26K
- Cherian VergheseNorristown$16.3M
- Steven ArnoldPhiladelphia$4.1M
- Paul GrossAllentown$4.1M
- Shivkumar HattiMedia$4M
- Rebecca RomaPittsburgh$3.3M
- Matthew BergerMoosic$2.4M
- Michael ThasePhiladelphia$2.2M
- Robert NelsonWyomissing$2.2M
- Mark MattaNew Castle$847K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.